Recombinant Human PILR-alpha Fc Chimera Protein, CF

R&D Systems, part of Bio-Techne | Catalog # 10802-PR

R&D Systems, part of Bio-Techne
Catalog #
Availability
Size / Price
Qty
10802-PR-050
Print Quote
Bulk Order
100% Guarantee

Key Product Details

Source

CHO

Accession #

Q9UKJ1.3

Conjugate

Unconjugated

Applications

Bioactivity

View all PILR-alpha Proteins and Enzymes »

Product Specifications

Source

Chinese Hamster Ovary cell line, CHO-derived human PILR-alpha protein
Human PILR-alpha
(Thr25-Thr196)
Accession # Q9UKJ1.3		 IEGRMD Human IgG1
(Pro100-Lys330)
N-terminus C-terminus

Purity

>95%, by SDS-PAGE visualized with Silver Staining and quantitative densitometry by Coomassie® Blue Staining.

Endotoxin Level

<0.10 EU per 1 μg of the protein by the LAL method.

N-terminal Sequence Analysis

Thr25

Predicted Molecular Mass

46 kDa

SDS-PAGE

57-64 kDa, under reducing conditions

Activity

Measured by its binding ability in a functional ELISA.
When Recombinant Human PANP Fc Chimera (Catalog # 7920-PN) is coated at 5.00 µg/mL (100 μL/well), Recombinant Human PILR- alpha Fc Chimera binds with an ED50 of 0.150- 0.900 μg/mL.

Scientific Data Images for Recombinant Human PILR-alpha Fc Chimera Protein, CF

Recombinant Human PILR-alpha Fc Chimera Protein SDS-PAGE.

2 μg/lane of Recombinant Human PILR-alpha Fc Chimera (Catalog # 10802-PR) was resolved with SDS-PAGE under reducing (R) and non-reducing (NR) conditions and visualized by Coomassie® Blue staining, showing bands at 57-64 kDa and 114-128 kDa, respectively.

Formulation, Preparation and Storage

10802-PR
Formulation Lyophilized from a 0.2 μm filtered solution in PBS with Trehalose.
Reconstitution Reconstitute at 500 μg/mL in PBS.
Shipping The product is shipped at ambient temperature. Upon receipt, store it immediately at the temperature recommended below.
Stability & Storage Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
  • 12 months from date of receipt, -20 to -70 °C as supplied.
  • 1 month, 2 to 8 °C under sterile conditions after reconstitution.
  • 3 months, -20 to -70 °C under sterile conditions after reconstitution.

Background: PILR-alpha

Paired immunoglobulin-like type 2 receptor-alpha (PILRA) is one of two members that belong to a small family of immunoregulatory Ig-superfamily receptors (1-4). It is a counterpart to PILRB and the PILRs represent one of many pairs of Ig-like domain-containing receptors that participate in immune regulation (1, 2). Mature human PILRA consists of an extracellular domain (ECD) with one V-type Ig-like domain, a transmembrane domain, and a cytoplasmic domain with two immunoreceptor Tyr‑based inhibitory (ITIM) motifs. Given that ITIMs are known to interact with phosphatases such as PTPN6 and PTPN11, the presence of these motifs makes PILRA an inhibitory receptor (1-4). The ECD of human PILRA shares 42% and 40% amino acid sequence identity with mouse and rat PILRA, respectively. Three potential isoforms for human PILRA have been reported. PILRA is expressed by neutrophils, macrophages, monocytes, mast cells, APCs, microglia, neurons, cardiac muscle and renal proximal plus pancreatic duct eipthelium (4, 7, 8). It has multiple binding partners, including CD99 (4, 9), glycoprotein B/gB of HSV1 (in human) (7), PANP (PILR-associated neural protein) (8) and NPDC1 plus collectin-12 (10). Although PILRA and PILRB are highly similar in their ECD amino acid sequence, they do not necessarily share the same ligands, as PILRB fails to bind to gB and PANP (8, 10). PILRA binding appears to be dependent upon the presence of a poorly-defined peptide sequence coupled to a sialylated, O-linked carbohydrate motif but its exact function remains unclear (5, 9-12). Up-regulation of PILRA in the early stage of immune reaction and its subsequent binding to CD99 may lead to a down-regulation of the inflammatory response (10). Genome-wide association studies (GWAS) have linked PILRA to Alzheimer's Disease (AD) through association of PILRB with ZCWPW1 (13,14). It was further supported that ZCWPW1 locus SNP rs1476679 was associated with reduced PILRA levels suggesting a potential role for the gene in AD (15). The missense variant (G78R, rs1859788) of PILRA is thought to be the causal allele for the confirmed AD risk locus. The variant reduced the binding of PILRA to several ligands including a novel ligand, complement component 4A, and herpes simplex virus 1 (HSV-1) glycoprotein B (16). The observed protection from AD risk by PILRA G78R variant provided a new candidate for the therapeutic target.

References

  1. Wilson, M.D. et al. (2006) Physiol. Genomics 27:201.
  2. Lanier, L.L. (2001) Curr. Opin. Immunol. 13:326.
  3. Fournier, N. et al. (2000) J. Immunol. 165:1197.
  4. Shiratori, I. et al. (2004) J. Exp. Med. 199:525.
  5. Mousseau, D.D. et al. (2000) J. Biol. Chem. 275:4467.
  6. SwissProt Accession # Q9UKJ1.
  7. Tato, C.M. et al. (2012) PLoS ONE 7:e31680.
  8. Satoh, T. et al. (2008) Cell 132:935.
  9. Tabata, S. et al. (2008),J. Biol. Chem. 283:8893.
  10. Sun, Y. et al. (2012) J. Biol. Chem. 287:15837.
  11. Wang, J. et al. (2008) J. Biol. Chem. 180:1686.
  12. Arii, J. et al. (2010) J. Virol. 84:10733.
  13. Karch, CM. et al. (2016) PLoS ONE. 11:1-22.
  14. Allen, M. et al. (2015) Neurol Genet. 1:e15 (PubMed: 27066552).
  15. Patel, T. et al. (2018) Neurolpathol Appl Neurobiol. 44(5):506.
  16. Rathore, N. et al. (2018) PLoS Genet. 14(11):e1007427.

Long Name

Paired-Ig-likeType 2 Receptor alpha

Alternate Names

FDF03, PILRA, PILRalpha

Entrez Gene IDs

29992 (Human); 231805 (Mouse); 288568 (Rat)

Gene Symbol

PILRA

UniProt

Q9UKJ1.3

Additional PILR-alpha Products

Product Documents for Recombinant Human PILR-alpha Fc Chimera Protein, CF

Product Datasheets

Certificate of Analysis

To download a Certificate of Analysis, please enter a lot number in the search box below.

Note: Certificate of Analysis not available for kit components.

Download SDS

Product Specific Notices for Recombinant Human PILR-alpha Fc Chimera Protein, CF

For research use only

Privacy and Cookie Policy
Site Map
© Copyright 2024 Bio-Techne. All Rights Reserved.